The New Paper

November 9, 2020

Pfizer announces interim results from coronavirus vaccine study

Pfizer and BioNTech announced that their coronavirus vaccine was found to be over 90% effective based on interim results from late-stage clinical trials. The ongoing Phase 3 trials began in July with over 40k participants, and the interim results released today were based on 94 patients. The companies expect to seek emergency use authorization from the FDA in late November after certain safety milestones are achieved.

More context: The US government previously announced plans to purchase 100M vaccines from Pfizer and BioNTech as part of “Operation Warp Speed.” The companies noted that they expect to produce up to 50 million vaccine doses this year and up to 1.3B in 2021.

Extra: Here’s a tracker of vaccines and treatments currently in development.

This story is from the November 9, 2020 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.